Mike Peters, of Dyserth, was admitted to The Christie hospital in Manchester in January. The father-of-two, who is married to Jules, has been undergoing Chimeric Antigen Receptor T-Cell Therapy (CAR-T ...

COPENHAGEN, Denmark I March 10, 2025 I Genmab A/S (Nasdaq: GMAB) announced today that Johnson & Johnson (J&J) has decided that it will not exercise ...

We recently compiled a list of the 10 Cash-Rich Undervalued Stocks To Invest In. In this article, we are going to take a look ...

During a Case-Based Roundtable® event, Natalie Galanina, MD, reviewed how outcomes have changed in patients with primary ...

Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more systemic treatments [ID6338] Technology appraisal guidance TBC ERC1671 for treating progressed or recurrent grade IV ...

With a portfolio of marketed products, including EPKINLY, TEPKINLY, and Tivdak, and a robust pipeline featuring Epcoritamab and tisotumab vedotin, it’s advancing groundbreaking treatments in ...

Highlights from Woyach, professor in the division of hematology at The Ohio State University, include a study that evaluated epcoritamab (Epkinly; Genmab, AbbVie) monotherapy, and another that ...

Value is just one of the five Stock Grades included in our A+ Investor service. AAII members can see the top-graded stocks—those with grades of A or B for value, growth, momentum, earnings estimate ...

Bispecific antibodies offer outpatient treatment options, increasing access to advanced therapies in community settings and reducing the burden of travel for patients. Recent approvals and ...

Results from the Phase Ib/II EPCORE NHL-2 trial demonstrate that the combination of epcoritamab, a CD3xCD20 bispecific antibody, and GemOx (gemcitabine plus oxaliplatin) offers deep and durable ...

DelveInsight’s, “Diffuse Large B-Cell Lymphoma Pipeline Insight” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Diffuse Large B-Cell Lymphoma pipeline ...

Combining epcoritamab-bysp with standard chemotherapy significantly improved response for patients with relapsed/refractory DLBCL. The regimen also significantly extended survival. The addition of ...